News
TSHA
3.720
-1.33%
-0.050
Piper Sandler Sticks to Its Buy Rating for Taysha Gene Therapies (TSHA)
TipRanks · 18h ago
Weekly Report: what happened at TSHA last week (1109-1113)?
Weekly Report · 4d ago
Taysha Earnings Call Highlights Gene Therapy Launch Readiness
TipRanks · 6d ago
BMO Capital Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
TipRanks · 11/13 16:55
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
TipRanks · 11/13 14:38
Taysha Gene Therapies (TSHA) Receives a Buy from Canaccord Genuity
TipRanks · 11/13 14:06
Taysha Q3 Loss Widens On Higher Expenses; REVEAL 6-Month Interim Data Due In H1'27
NASDAQ · 11/13 09:30
Taysha (TSHA) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/13 06:13
Taysha Gene Therapies, Inc. Reports Third Quarter 2026 Financial Results and Corporate Update
NASDAQ · 11/13 04:41
Taysha Gene Therapies Q3 2026 Earnings Call Transcript
Benzinga · 11/12 14:53
Taysha Gene Therapies reports Q3 EPS (10c), consensus (12c)
TipRanks · 11/12 13:00
Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.03
Seeking Alpha · 11/12 12:39
*Taysha Gene Therapies 3Q Rev $0.00 >TSHA
Dow Jones · 11/12 12:32
Press Release: Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 11/12 12:30
Press Release: Taysha Gene Therapies Reports -2-
Dow Jones · 11/12 12:30
*Taysha Gene Therapies 3Q Loss/Shr 10c >TSHA
Dow Jones · 11/12 12:30
Here are the major earnings before the open Thursday
Seeking Alpha · 11/11 23:00
Taysha Gene Therapies Q3 2026 Earnings Preview
Seeking Alpha · 11/11 15:43
Weekly Report: what happened at TSHA last week (1102-1106)?
Weekly Report · 11/09 09:36
Weekly Report: what happened at TSHA last week (1026-1030)?
Weekly Report · 11/02 09:36
More
Webull provides a variety of real-time TSHA stock news. You can receive the latest news about Taysha Gene Therapies, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.